Dr. Huihui Li 李慧慧
Chief Physician
Breast Surgery (II), Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Individualized comprehensive treatment for breast cancer, including chemotherapy, biological therapy, targeted therapy, endocrine therapy, and immunotherapy. Particular experience in treating refractory breast cancer.
Dr. Li is Director of the Department of Medical Oncology for Breast Cancer and a Chief Physician. Holding a doctorate from Peking Union Medical College and having completed postdoctoral work at Shandong University, Dr. Li trained under Academicians Xu Binghe and Yu Jinming. A visiting scholar at MD Anderson Cancer Center, Dr. Li serves as a postdoctoral and graduate supervisor.
Professional roles
- Vice Chair, Breast Expert Committee, Shandong Clinical Oncology Society
- Vice Chair (Youth), Tumor Molecular Markers and Targeted Therapy Professional Committee, Shandong Immunological Society
- Member, Tumor Cardiology Group, Cardiovascular Branch, Chinese Medical Association
- Youth Editorial Board Member, Chinese Journal of Cancer Prevention and Treatment
Name order: in Chinese the family name comes first (Li Huihui). Papers usually list the name as Huihui Li or Li H.
Selected publications
47 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Control, 2026 (senior author): Real-World Outcomes With Inetetamab-Based Regimens for HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Analysis in China. PubMed 41552962
- Cancer Innov, 2025 (senior author): Identification of significant single-nucleotide polymorphisms associated with breast cancer recurrence and metastasis using GWAS. PubMed 39777116
- Clin Breast Cancer, 2024 (senior author): Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study. PubMed 38729821
- Clin Transl Med, 2024 (senior author): Efficacy and safety of pyrotinib combined with albumin-bound paclitaxel as first-line treatment for HER2-positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single-arm, phase 2 prospective clinical trial. PubMed 38738791
- Elife, 2023 (senior author): Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study. PubMed 37929934
- Cancer Med, 2023 (senior author): The metastasis patterns and their prognostic features in patients with de novo metastatic breast cancer of different ages. PubMed 37688399
- Front Genet, 2023 (senior author): Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer. PubMed 37007962
- Cancer Med, 2023 (senior author): Efficacy and safety of pyrotinib-containing regimen in the patients with HER2-positive metastatic breast cancer: A multicenter real-world study. PubMed 35894763
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion